Alexza Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Alexza Pharmaceuticals, Inc. (ALXA)

Q2 2012 Earnings Call

August 8, 2012 5:00 pm ET

Executives

Mark K. Oki – Senior Vice President-Finance, Chief Financial Officer and Secretary

Thomas B. King – President and Chief Executive Officer

Analysts

Roy Buchanan – JMP Securities

Steve Brozak – WBB Securities, LLC

Presentation

Operator

Good afternoon, everyone, and welcome to the Alexza Pharmaceuticals 2012 Second Quarter Financial Results and General Business Update Conference Call. At this time, all participants are in a listen-only mode for the conference call. Following the prepared remarks, there will be a question-and-answer session. (Operator Instructions) Today’s conference is also being recorded. And if you have any objections, you may disconnect at this time.

I would now like to turn today’s conference over to Mr. Mark Oki of Alexza. Mr. Oki, you may begin.

Mark K. Oki

Thank you. Good afternoon and welcome to our 2012 second quarter financial results and general business update conference call. Before we get started, I would like to remind you that the matters discussed on this call contain forward-looking statements that involve risks and uncertainties, including those related to the Company’s ability to address the issues raised in the May 2012 CRL, the eventual prospects that ADASUVE will be approved for marketing in the U.S. or other locations, and timing of the EMA review of the ADASUVE MAA, our ability to commercialize products, the timing of the commercialization of our products, our projected revenue and expenses, and the ability of Alexza to support operations based on existing cash resources.

Actual results may differ materially from the results predicted, and recorded results should not be considered an indication of future performance. These and other risk factors are more fully discussed in our quarterly report on Form 10-Q that we filed with the SEC earlier today most particularly under the caption Risk Factors. Alexza disclaims any obligation to update or revise any forward-looking statement made on this call as a result of new information or future developments.

If you liked this article you might like

3 Stocks Pushing The Drugs Industry Lower

Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals

Why to Buy These 5 Under-$10 Stocks ASAP

5 Stocks Under $10 Set to Soar

7 Under-$10 Stocks Racing Higher